Bibliografía del artículo
1. Guía de buena práctica clínica en Geriatría: Osteoporosis. Sociedad Española de Geriatría y Gerontología y Scientific Communication Management, 2004.
2. Díaz Curiel M, Moro Alvarez MJ. Epidemiología de la osteoporosis y de las fracturas osteoporóticas. Medicine 9(Extr 1):15-18, 2006.
3. Díaz Curiel M, García JJ, Carrasco JL, y col. Prevalencia de osteoporosis determinada por densitometría en la población femenina española. Med Clin (Barc) 116:86-8, 2001.
4. Siris ES, Brenneman SK, Barrett-Connor E, y col. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17(4):565-74, 2006.
5. Gluer CC, for the International Quantitative Ultrasound Consensus Group. Quantitative ultrasound Techniques for the assessment of osteoporosis: expert agreement on current status. J Bone Miner Res 12:1280-8, 1997.
6. Aragonés R, Orozco P y Grupo de Osteoporosis de la Societat Catalana de Medicina Familiar i Comunitaria. Aten Primaria 30:350-6, 2002.
7. Diéz-Pérez A, Marín F, Vila J y col. Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women. J Clin Densitom 6:237-45, 2003.
8. Gómez de Tejada MJ, Sosa M. El diagnóstico de la osteoporosis. Medicine 9(Extr 1):19-26, 2006.
9. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40(6):1581-7, 2007.
10. Bauer DC, Mundy GR, Jamal SA y col. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164(2):146-52, 2004.
11. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 58(1):3-18, 2006.
12. Sosa M, Saavedra P, Alegre J y col. Grupo de investigación en ultrasonidos y metabolismo mineral (GIUMO). Prevalencia de osteoporosis en la población española por ultrasonografía de calcáneo en función del criterio diagnóstico utilizado. Datos del estudio GIUMO. Rev Clin Esp 203:329-33, 2003.
13. Navas FJ, Fernández FJ, Bayona I, Mingo T, De la Fuente MM, Cacho A. Prevalencia de osteoporosis en ancianos institucionalizados, mediante ultrasonografía de calcáneo. An Med Interna 23(8):374-8, 2006.
14. Dargent-Molina P, Piault S, Bréart G; EPIDOS Study Group. A comparison of different screening strategies to identify elderly women at high risk of hip fracture: results from the EPIDOS prospective study. Osteoporos Int 14(12):969-77, 2003.
15. Schott AM, Hans D, Duboeuf F y col; EPIDOS Study Group. Quantitative ultrasound parameters as well as bone mineral density are better predictors of trochanteric than cervical hip fractures in elderly women. Results from the EPIDOS study. Bone 37(6):858-63, 2005.
16. Huopio J, Kröger H, Honkanen R, Jurvelin J, Saarikoski S, Alhava E. Calcaneal ultrasound predicts early postmenopausal fractures as well as axial BMD. A prospective study of 422 women. Osteoporos Int 15:190-5, 2004.
17. Durosier C, Hans D, Krieg MA y col. Combining clinical factors and quantitative ultrasound improves the detection of women both at low and high risk for hip fracture. Osteoporos Int 18:1651-1659, 2007.
18. Sosa M, Saavedra P, Muñoz-Torres M y col.; and the GIUMO Study Group. Quantitative ultrasound calcaneus measurements: normative data and precision in the Spanish population. Osteoporos Int 13:487-92, 2002.
19. Mundy G, Garrett R, Harris S y col. Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446):1946-9, 1999.
20. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-10, 2000.
21. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-16, 2000.
22. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1.year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584-7, 2001.
23. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218-9, 2000.
24. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874-7, 2001.
25. Grasser WA, Baumann AP, Petras SF y col. Regulation of osteoclast differentiation by statins. Musculoskelet Neuronal Interact 3(1):53-62, 2003.
26. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 17:2004-8, 2002.
27. Lupattelli G, Scarponi AM, Vaudo G y col. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism 53(6):744-8, 2004.
28. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21(10):1636-41, 2001.
29. Yao W, Farmer R, Cooper R y col. Simvastatin did not prevent nor restore ovariectomy-induced bone loss in adult rats. J Musculoskelet Neuronal Interact 6(3):277-83, 2006.
30. Van Staa TP, Wegman S, De Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 285:1850-5, 2001.
31. Ray WA, Daugherty JR, Griffin MR. Lipid lowering agents and the risk of hip fracture in a Medical population. Inj Prev 8:276-9, 2002.
32. Ravn P, Cizza G, Bjarnason NH y col. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14(9):1622-7, 1999.
33. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res 15(2):322-3, 2000.